Product Information
EZETIMIBE-SIMVASTATIN 10-20 MG is a generic product labeled by Amneal Pharmaceuticals NY LLC, priced at $0.3170 per EA under NDC 69238115603. Its NADAC has been published 413 times since Dec 27, 2017.
FDA first approved this application on Nov 21, 2017.
Strength
10; 20 mg/1; mg/1
Manufacturer
Amneal Pharmaceuticals NY LLCNDC
69238115603
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
11/19/2025
Active Ingredients
EZETIMIBE; SIMVASTATINApproval Type
Generic (ANDA)
FDA Application
ANDA208831FDA Approved
11/21/2017
On Market Since
11/21/2017
Pharmacological Classes
Price Statistics
The NADAC for EZETIMIBE-SIMVASTATIN 10-20 MG has been published 413 times since Dec 27, 2017, and over the history we have for it it has declined 88.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3170 per EA |
|---|---|
| All-time high | $2.8281 (Jan 10, 2018) |
| All-time low | $0.3050 (Mar 20, 2024) |
| 52-week high | $0.3917 |
| 52-week low | $0.3170 |
| Median price | $0.7427 |
| Average price | $1.0754 |
| Largest weekly change | +46.7% (Jun 19, 2024) |
| Weeks tracked | 413 |
| Tracking since | Dec 27, 2017 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
-19.1%
3Y
-11.1%
5Y
-59.4%
All
-88.8%
Last surveyed Nov 19, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 37% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amneal Pharmaceuticals NY LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ezetimibe and Simvastatin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dietary Cholesterol Absorption Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EZETIMIBE-SIMVASTATIN 10-20 MG?
The current National Average Drug Acquisition Cost (NADAC) for EZETIMIBE-SIMVASTATIN 10-20 MG, manufactured by Amneal Pharmaceuticals NY LLC, is $0.3170 per EA (NDC 69238115603), effective Nov 19, 2025.
How has the price of EZETIMIBE-SIMVASTATIN 10-20 MG changed over time?
Over the history we have for it, the NADAC for EZETIMIBE-SIMVASTATIN 10-20 MG has declined 88.8%. It has been tracked across 413 weekly CMS publications since Dec 27, 2017.
What are the highest and lowest recorded NADAC prices for EZETIMIBE-SIMVASTATIN 10-20 MG?
Since Dec 27, 2017, the NADAC for EZETIMIBE-SIMVASTATIN 10-20 MG has ranged from a low of $0.3050 (Mar 20, 2024) to a high of $2.8281 (Jan 10, 2018), with a median of $0.7427 per EA.
Are there cheaper alternatives to EZETIMIBE-SIMVASTATIN 10-20 MG?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, EZETIMIBE-SIMVASTATIN 10-20 MG, is $0.1985 per EA — about 37% below EZETIMIBE-SIMVASTATIN 10-20 MG.
Who manufactures EZETIMIBE-SIMVASTATIN 10-20 MG?
EZETIMIBE-SIMVASTATIN 10-20 MG (NDC 69238115603) is labeled by Amneal Pharmaceuticals NY LLC, and CMS classifies it as a generic product.